RNS Number : 7446R
Santander UK Plc
04 February 2026

SANTANDER UK PLC
€35 BILLION GLOBAL COVERED BOND PROGRAMME
PUBLICATION OF SUPPLEMENTARY PROSPECTUS

The following supplementary prospectus (the **Supplementary Prospectus**) has been approved by the UK Financial Conduct Authority and is available for viewing:

Supplementary Prospectus dated 4 February 2026 to the prospectus dated 21 March 2025 as supplemented on 30 April 2025, 30 July 2025 and 29 August 2025 relating to the €35,000,000,000 Global Covered Bond Programme of Santander UK plc (the **Prospectus**).

To view the full Supplementary Prospectus please paste the following URL into the address bar of your browser:

http://www.rns-pdf.londonstockexchange.com/rns/7446R_1-2026-2-4.pdf

A copy of the Supplementary Prospectus has been submitted to the National Storage Mechanism and will shortly be available for inspection at: https://data.fca.org.uk/#/nsm/nationalstoragemechanism.

The Supplementary Prospectus will also be available for viewing via:

https://www.santander.co.uk/about-santander/investor-relations/santander-uk-covered-bonds

For further information, please contact:

Funding, Asset Rotation and Investor Relations
Santander UK plc
2 Triton Square
Regent's Place
London NW1 3AN

Email: fair@santander.co.uk

DISCLAIMER - INTENDED ADDRESSEES

Please note that the information contained in the Supplementary Prospectus and the Prospectus may be addressed to and/or targeted at persons who are residents of particular countries only (as specified in the Prospectus) and is not intended for use and should not be relied upon by any person outside these countries and/or to whom the offer contained in the Prospectus is not addressed. Prior to relying on the information contained in the Prospectus you must ascertain from such Prospectus whether or not you are part of the intended addressees of the information contained therein.

This publication of the Supplementary Prospectus does not constitute an offer of securities for sale in the United States. The securities described in the Prospectus have not been, and will not be, registered under the U.S. Securities Act of 1933, as amended (the **Securities Act**), or under any relevant securities laws of any state of the United States of America, and may not be offered or sold in the United States of America or to, or for the benefit of, U.S. persons (as defined in Regulation S of the Securities Act), unless the securities are registered under the Securities Act or an exemption from the registration requirements of the Securities Act is available.

Your right to access this service is conditional upon your compliance with the above requirement.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further

information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

PSPDZGGZFDDGVZM